Interaction between tobramycin and CSA-13 on clinical isolates of Pseudomonas aeruginosa in a model of young and mature biofilms

Applied Microbiology and Biotechnology

Volumn 88, Issue 1, 2010, Pages 251-263

  Nagant, Carole ^a   Tré Hardy, Marie ^a   El Ouaaliti, Malika ^a   Savage, Paul ^b   Devleeschouwer, Michel ^a   Dehaye, Jean Paul ^a  

^a UNIVERSITÉ LIBRE DE BRUXELLES   (Belgium)

^b N243 Eyring Science Center   (United States)

Author keywords

Aminoglycoside; Antimicrobial peptides; Cystic fibrosis

Indexed keywords

AMINOGLYCOSIDES; ANTIMICROBIAL PEPTIDE; BACTERICIDAL ACTIVITY; BACTERICIDAL EFFECTS; CATIONIC STEROID; CHOLIC ACIDS; CLINICAL ISOLATES; CLINICAL STRAINS; CYSTIC FIBROSIS; EUKARYOTIC CELLS; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; LOW CONCENTRATIONS; OUTER MEMBRANE; P.AERUGINOSA; PLASMA MEMBRANES; PSEUDOMONAS AERUGINOSA; PULMONARY INFECTIONS; TOBRAMYCIN; TOXIC DERIVATIVES;

ANTIBIOTICS; BACTERIA; BACTERICIDES; BIOFILMS; BIOFILTERS; CELL CULTURE; CELL MEMBRANES; CONCENTRATION (PROCESS); ENDOTHELIAL CELLS; PEPTIDES;

STRAIN;

ANTIINFECTIVE AGENT; CSA 13; TOBRAMYCIN; UNCLASSIFIED DRUG;

ANTIBIOTICS; ANTIMICROBIAL ACTIVITY; BACTERIUM; BIOFILM; DIGESTIVE SYSTEM DISORDER; DISEASE TREATMENT; INHIBITOR; MEMBRANE; PEPTIDE; RESPIRATORY DISEASE; STEROID; TOXIC MATERIAL;

ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL STRAIN; BACTERICIDAL ACTIVITY; BACTERIUM ISOLATE; BIOFILM; CONTROLLED STUDY; DRUG EFFECT; DRUG TOLERABILITY; ENDOTHELIUM CELL; EUKARYOTIC CELL; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PLANKTON; PSEUDOMONAS AERUGINOSA; TREATMENT RESPONSE;

ANTI-BACTERIAL AGENTS; BIOFILMS; CELL MEMBRANE PERMEABILITY; CHOLIC ACID; DRUG INTERACTIONS; ENDOTHELIAL CELLS; HUMANS; MICROBIAL SENSITIVITY TESTS; MICROBIAL VIABILITY; PSEUDOMONAS AERUGINOSA; TOBRAMYCIN;

EUKARYOTA; PSEUDOMONAS AERUGINOSA;

EID: 77955848868     PISSN: 01757598     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00253-010-2748-3     Document Type: Article

References (40)

1. R Bals JM Wilson 2003 Cathelicidins-a family of multifunctional antimicrobial peptides Cell Mol Life Sci 60 711 720 10.1007/s00018-003-2186-9 1:CAS:528:DC%2BD3sXktlyjurk%3D
2. T Bjarnsholt P∅ Jensen MJ Fiandaca J Pedersen CR Hansen CB Andersen T Pressler M Givskov N Høiby 2009 Pseudomonas aeruginosa biofilms in the respiratory tract of cystic fibrosis patients Pediatr Pulmonol 44 547 558 10.1002/ppul.21011
3. RC Boucher 2004 New concepts of the pathogenesis of cystic fibrosis lung disease Eur Respir J 23 146 158 10.1183/09031936.03.00057003 1:CAS:528:DC%2BD2cXhtFGntr4%3D
4. R Bucki AG Sostarecz FJ Byfield PB Savage PA Janmey 2007 Resistance of the antibacterial agent ceragenin CSA-13 to inactivation by DNA or F-actin and its activity in cystic fibrosis sputum J Antimicrob Chemother 60 535 545 10.1093/jac/dkm218 1:CAS:528:DC%2BD2sXpt1Clsrw%3D
5. JN Chin RN Jones HS Sader PB Savage MJ Rybak 2008 Potential synergy activity of the novel ceragenin, CSA-13, against clinical isolates of Pseudomonas aeruginosa, including multidrug-resistant P. aeruginosa J Antimicrob Chemother 61 365 370 10.1093/jac/dkm457 1:CAS:528:DC%2BD1cXptlGrtQ%3D%3D
6. th Ed. Approved Standard. M7-A6. CLSI, Wayne, PA, USA.
7. TR de Kievit BH Iglewski 2000 Bacterial quorum sensing in pathogenic relationships Infect Immun 68 4839 4849 10.1128/IAI.68.9.4839-4849.2000
8. AL Dela Vega AH Delcour 1996 Polyamines decrease Escherichia coli outer membrane permeability J Bacteriol 178 3715 3721 1:CAS:528:DyaK28XjvFegsLg%3D
9. B Ding Q Guan JP Walsh JS Boswell TW Winter ES Winter SS Boyd C Li PB Savage 2002 Correlation of the antibacterial activities of cationic peptide antibiotics and cationic steroid antibiotics J Med Chem 45 663 669 10.1021/jm0105070 1:CAS:528:DC%2BD3MXpt1Cnsbc%3D
10. RF Epand PB Savage RM Epand 2007 Bacterial lipid composition and the antimicrobial efficacy of cationic steroid compounds (Ceragenins) Biochim Biophys Acta 1768 2500 2509 10.1016/j.bbamem.2007.05.023 1:CAS:528: DC%2BD2sXhtFGrsrrN
11. RM Epand RF Epand PB Savage 2008 Ceragenins (cationic steroid compounds), a novel class of antimicrobial agents Drug News Perspect 21 307 311 10.1358/dnp.2008.21.6.1246829 1:CAS:528:DC%2BD1cXhtl2gt7bF
12. PA Flume 2008 A role for aerosolized antibiotics Pediatr Pulmonol 43 S29 S34 10.1002/ppul.20731
13. SK Fridkin CD Steward JR Edwards ER Pryor JE McGowan Jr LK Archibald RP Gaynes FC Tenover 1999 Surveillance of antimicrobial use and antimicrobial resistance in United States hospitals: project ICARE phase 2. Project Intensive Care Antimicrobial Resistance Epidemiology (ICARE) hospitals Clin Infect Dis 29 245 252 10.1086/520193 1:STN:280:DyaK1MvgsVeksg%3D%3D
14. WJ Gooderham RE Hancock 2009 Regulation of virulence and antibiotic resistance by two-component regulatory systems in Pseudomonas aeruginosa FEMS Microbiol Rev 33 279 294 10.1111/j.1574-6976.2008.00135.x 1:CAS:528: DC%2BD1MXivFegsbs%3D
15. E Guaní-Guerra T Santos-Mendoza SO Lugo-Reyes LM Terán 2010 Antimicrobial peptides: general overview and clinical implications in human health and disease Clin Immunol 135 1 11 10.1016/j.clim.2009.12.004
16. JS Gunn 2001 Bacterial modification of LPS and resistance to antimicrobial peptides J Endotoxin Res 7 57 62 1:CAS:528:DC%2BD3MXkvFeitr4%3D
17. E Isogai H Isogai K Takahashi K Okumura PB Savage 2009 Ceragenin CSA-13 exhibits antimicrobial activity against cariogenic and periodontopathic bacteria Oral Microbiol Immunol 24 170 172 1:CAS:528:DC%2BD1MXjvVyrtLc%3D
18. JB Kaplan 2010 Biofilm dispersal: mechanisms, clinical implications, and potential therapeutic uses J Dent Res 89 205 218 10.1177/0022034509359403 1:CAS:528:DC%2BC3cXjtFOnsLY%3D
19. DH Kwon CD Lu 2006 Polyamines induce resistance to cationic peptide, aminoglycoside, and quinolone antibiotics in Pseudomonas aeruginosa PAO1 Antimicrob Agents Chemother 50 1615 1622 10.1128/AAC.50.5.1615-1622.2006 1:CAS:528:DC%2BD28XksVKktr8%3D
20. K Leszczyńska A Namiot DE Fein Q Wen Z Namiot PB Savage S Diamond PA Janmey R Bucki 2009 Bactericidal activities of the cationic steroid CSA-13 and the cathelicidin peptide LL-37 against Helicobacter pylori in simulated gastric juice BMC Microbiol 9 187 10.1186/1471-2180-9-187
21. C Li A Peters E Meredith GH Allman PB Savage 1998 Design and synthesis of potent sensitizers of Gram-negative bacteria based on a cholic acid scaffolding J Am Chem Soc 120 2961 2962 10.1021/ja973881r 1:CAS:528:DyaK1cXit1Wgu7c%3D
22. C Li LP Budge CD Driscoll BM Willardson GW Allman PB Savage 1999 Incremental conversion of outer-membrane permeabilizers into potent antibiotics for gram-negative bacteria J Am Chem Soc 121 931 940 10.1021/ja982938m 1:CAS:528:DyaK1MXlvFCisA%3D%3D
23. B Loh C Grant RE Hancock 1984 Use of the fluorescent probe 1-N-phenylnaphthylamine to study the interactions of aminoglycoside antibiotics with the outer membrane of Pseudomonas aeruginosa Antimicrob Agents Chemother 26 546 551 1:CAS:528:DyaL2MXjtFWn
24. DL MacLeod LE Nelson RM Shawar BB Lin LG Lockwood JE Dirks GH Miller JL Burns RL Garber 2000 Aminoglycoside resistance mechanisms for cystic fibrosis Pseudomonas aeruginosa isolates are unchanged by long-term, intermittent, inhaled tobramycin treatment J Infect Dis 181 1180 1184 10.1086/315312 1:CAS:528:DC%2BD3cXivVOns74%3D
25. J Manos J Arthur B Rose P Tingpej C Fung M Curtis JS Webb H Hu S Kjelleberg MD Gorrell P Bye C Harbour 2008 Transcriptome analyses and biofilm-forming characteristics of a clonal Pseudomonas aeruginosa from the cystic fibrosis lung J Med Microbiol 57 1454 1465 10.1099/jmm.0.2008/005009-0 1:CAS:528:DC%2BD1MXhtVWru7g%3D
26. 4- in the regulation of the intracellular calcium in rat submandibular glands J Cell Physiol 161 243 248 10.1002/jcp.1041610208
27. RD Monds GA O'Toole 2009 The developmental model of microbial biofilms: ten years of a paradigm up for review Trends Microbiol 17 73 87 10.1016/j.tim.2008.11.001 1:CAS:528:DC%2BD1MXit1Okt7k%3D
28. S Moreau-Marquis BA Stanton GA O'Toole 2008 Pseudomonas aeruginosa biofilm formation in the cystic fibrosis airway Pulm Pharmacol Ther 21 595 599 10.1016/j.pupt.2007.12.001 1:CAS:528:DC%2BD1cXoslWntb0%3D
29. S Moreau-Marquis JM Bomberger GG Anderson A Swiatecka-Urban S Ye GA O'Toole BA Stanton 2008 The DeltaF508-CFTR mutation results in increased biofilm formation by Pseudomonas aeruginosa by increasing iron availability Am J Physiol Lung Cell Mol Physiol 295 L25 L37 10.1152/ajplung.00391.2007 1:CAS:528:DC%2BD1cXoslygsLk%3D
30. SM Moskowitz JM Foster J Emerson JL Burns 2004 Clinically feasible biofilm susceptibility assay for isolates of Pseudomonas aeruginosa from patients with cystic fibrosis J Clin Microbiol 42 1915 1922 10.1128/JCM.42.5. 1915-1922.2004 1:CAS:528:DC%2BD2cXkvFOjsLc%3D
31. J Overhage M Bains MD Brazas RE Hancock 2008 Swarming of Pseudomonas aeruginosa is a complex adaptation leading to increased production of virulence factors and antibiotic resistance J Bacteriol 190 2671 2679 10.1128/JB.01659-07 1:CAS:528:DC%2BD1cXkslyht7Y%3D
32. J Pollard J Wright Y Feng D Geng C Genberg PB Savage 2009 Activities of Ceragenin CSA-13 against established biofilms in an in vitro model of catheter decolonization Anti-Infect Agents Med Chem 8 290 294 1:CAS:528: DC%2BD1MXhs1Whur%2FL
33. U Römling B Fiedler J Bosshammer D Grothues J Greipel H von der Hardt B Tümmler 1994 Epidemiology of chronic Pseudomonas aeruginosa infections in cystic fibrosis J Infect Dis 170 1616 1621
34. KL Rosenthal 2006 Tweaking innate immunity: the promise of innate immunologicals as anti-infectives Can J Infect Dis Med Microbiol 17 307 314
35. S Saha PB Savage M Bal 2008 Enhancement of the efficacy of erythromycin in multiple antibiotic-resistant gram-negative bacterial pathogens J Appl Microbiol 105 822 828 10.1111/j.1365-2672.2008.03820.x 1:CAS:528: DC%2BD1cXht1amtbbN
36. PB Savage C Li U Taotafa B Ding Q Guan 2002 Antibacterial properties of cationic steroid antibiotics FEMS Microbiol Lett 217 1 7 10.1111/j.1574-6968. 2002.tb11448.x 1:CAS:528:DC%2BD38XoslGiu74%3D
37. I Stelmach A Korzeniewska W Stelmach 2008 Long-term benefits of inhaled tobramycin in children with cystic fibrosis: first clinical observations from Poland Respiration 75 178 181 10.1159/000101725 1:CAS:528:DC%2BD1cXjtVCgt7k%3D
38. Tré-Hardy M (2008) Etude de synergies médicamenteuses dans le traitement d'infections liées à des biofilms dans la mucoviscidose. Dissertation, Université libre de Bruxelles.
39. M Tré-Hardy H Traore N El Manssouri F Vanderbist M Vaneechoutte MJ Devleeschouwer 2009 Evaluation of long-term co-administration of tobramycin and clarithromycin in a mature biofilm model of cystic fibrosis clinical isolates of Pseudomonas aeruginosa Int J Antimicrob Agents 34 370 374 10.1016/j.ijantimicag.2009.04.010
40. D Worlitzsch R Tarran M Ulrich U Schwab A Cekici KC Meyer P Birrer G Bellon J Berger T Weiss K Botzenhart JR Yankaskas S Randell RC Boucher G Döring 2002 Effects of reduced mucus oxygen concentration in airway Pseudomonas infections of cystic fibrosis patients J Clin Invest 109 317 325 1:CAS:528:DC%2BD38XhtV2isLo%3D